nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Erlotinib—pancreatic cancer	0.352	0.525	CbGbCtD
Dolutegravir—UGT1A1—Irinotecan—pancreatic cancer	0.318	0.474	CbGbCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—LY6E—pancreatic cancer	0.0238	0.212	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—pancreatic cancer	0.00706	0.0628	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—HES1—pancreatic cancer	0.00667	0.0594	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SSTR1—pancreatic cancer	0.00651	0.058	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SSTR2—pancreatic cancer	0.00627	0.0558	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—pancreatic cancer	0.00504	0.0449	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—FOXM1—pancreatic cancer	0.00493	0.0439	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—SHH—pancreatic cancer	0.00454	0.0404	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—pancreatic cancer	0.004	0.0356	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—NFKBIA—pancreatic cancer	0.00383	0.0341	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—SST—pancreatic cancer	0.00357	0.0318	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—SMAD4—pancreatic cancer	0.00289	0.0257	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HES1—pancreatic cancer	0.00256	0.0228	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—FGF13—pancreatic cancer	0.00249	0.0222	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—pancreatic cancer	0.00246	0.0219	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—pancreatic cancer	0.00214	0.0191	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Irinotecan—pancreatic cancer	0.00185	0.00848	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—pancreatic cancer	0.00181	0.0161	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Gemcitabine—pancreatic cancer	0.0018	0.00826	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—pancreatic cancer	0.00176	0.0157	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—pancreatic cancer	0.00173	0.0154	CbGpPWpGaD
Dolutegravir—Inflammation—Fluorouracil—pancreatic cancer	0.00173	0.00792	CcSEcCtD
Dolutegravir—Blood creatinine increased—Tamoxifen—pancreatic cancer	0.00169	0.00773	CcSEcCtD
Dolutegravir—Myositis—Epirubicin—pancreatic cancer	0.00166	0.00762	CcSEcCtD
Dolutegravir—Renal impairment—Sunitinib—pancreatic cancer	0.00162	0.00743	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—pancreatic cancer	0.0016	0.0143	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Tamoxifen—pancreatic cancer	0.00159	0.00728	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Erlotinib—pancreatic cancer	0.00157	0.0072	CcSEcCtD
Dolutegravir—Myositis—Doxorubicin—pancreatic cancer	0.00154	0.00705	CcSEcCtD
Dolutegravir—Rash maculo-papular—Fluorouracil—pancreatic cancer	0.00152	0.00698	CcSEcCtD
Dolutegravir—Abdominal discomfort—Tamoxifen—pancreatic cancer	0.00149	0.00684	CcSEcCtD
Dolutegravir—Neutropenia—Tamoxifen—pancreatic cancer	0.00145	0.00667	CcSEcCtD
Dolutegravir—Blood creatinine increased—Sunitinib—pancreatic cancer	0.00144	0.00662	CcSEcCtD
Dolutegravir—Neutropenia—Erlotinib—pancreatic cancer	0.00144	0.0066	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—pancreatic cancer	0.00142	0.0126	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—pancreatic cancer	0.00141	0.0126	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Sunitinib—pancreatic cancer	0.00141	0.00645	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—pancreatic cancer	0.00139	0.0124	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Sunitinib—pancreatic cancer	0.00136	0.00623	CcSEcCtD
Dolutegravir—Renal failure—Erlotinib—pancreatic cancer	0.00135	0.00618	CcSEcCtD
Dolutegravir—Renal impairment—Irinotecan—pancreatic cancer	0.00133	0.00612	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—pancreatic cancer	0.00133	0.0118	CbGpPWpGaD
Dolutegravir—Serum creatinine increased—Epirubicin—pancreatic cancer	0.00133	0.00608	CcSEcCtD
Dolutegravir—Renal impairment—Gemcitabine—pancreatic cancer	0.0013	0.00596	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Erlotinib—pancreatic cancer	0.0013	0.00595	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—pancreatic cancer	0.00128	0.0114	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Docetaxel—pancreatic cancer	0.00128	0.00586	CcSEcCtD
Dolutegravir—Abdominal discomfort—Sunitinib—pancreatic cancer	0.00128	0.00586	CcSEcCtD
Dolutegravir—Inflammation—Docetaxel—pancreatic cancer	0.00125	0.00571	CcSEcCtD
Dolutegravir—Neutropenia—Sunitinib—pancreatic cancer	0.00125	0.00571	CcSEcCtD
Dolutegravir—Hepatitis—Tamoxifen—pancreatic cancer	0.00124	0.00571	CcSEcCtD
Dolutegravir—Hepatitis—Erlotinib—pancreatic cancer	0.00123	0.00565	CcSEcCtD
Dolutegravir—Serum creatinine increased—Doxorubicin—pancreatic cancer	0.00123	0.00562	CcSEcCtD
Dolutegravir—Urinary tract disorder—Erlotinib—pancreatic cancer	0.00122	0.00558	CcSEcCtD
Dolutegravir—Urethral disorder—Erlotinib—pancreatic cancer	0.00121	0.00554	CcSEcCtD
Dolutegravir—Hyperglycaemia—Sunitinib—pancreatic cancer	0.0012	0.00551	CcSEcCtD
Dolutegravir—Blood creatinine increased—Irinotecan—pancreatic cancer	0.00119	0.00545	CcSEcCtD
Dolutegravir—Renal failure—Sunitinib—pancreatic cancer	0.00117	0.00535	CcSEcCtD
Dolutegravir—Blood creatinine increased—Gemcitabine—pancreatic cancer	0.00116	0.00531	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—pancreatic cancer	0.00115	0.0102	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	0.00113	0.01	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Sunitinib—pancreatic cancer	0.00112	0.00515	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Gemcitabine—pancreatic cancer	0.00109	0.005	CcSEcCtD
Dolutegravir—Mental disorder—Erlotinib—pancreatic cancer	0.00108	0.00495	CcSEcCtD
Dolutegravir—Hepatitis—Sunitinib—pancreatic cancer	0.00107	0.00489	CcSEcCtD
Dolutegravir—Flatulence—Erlotinib—pancreatic cancer	0.00106	0.00484	CcSEcCtD
Dolutegravir—Urinary tract disorder—Sunitinib—pancreatic cancer	0.00105	0.00483	CcSEcCtD
Dolutegravir—Urethral disorder—Sunitinib—pancreatic cancer	0.00104	0.00479	CcSEcCtD
Dolutegravir—Neutropenia—Irinotecan—pancreatic cancer	0.00103	0.0047	CcSEcCtD
Dolutegravir—Neutropenia—Gemcitabine—pancreatic cancer	0.000999	0.00458	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.000981	0.00874	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—pancreatic cancer	0.000967	0.00861	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Gemcitabine—pancreatic cancer	0.000964	0.00442	CcSEcCtD
Dolutegravir—Immune system disorder—Sunitinib—pancreatic cancer	0.000963	0.00442	CcSEcCtD
Dolutegravir—Renal failure—Irinotecan—pancreatic cancer	0.000961	0.00441	CcSEcCtD
Dolutegravir—Renal failure—Gemcitabine—pancreatic cancer	0.000936	0.0043	CcSEcCtD
Dolutegravir—Mental disorder—Sunitinib—pancreatic cancer	0.000934	0.00428	CcSEcCtD
Dolutegravir—Renal impairment—Docetaxel—pancreatic cancer	0.000922	0.00423	CcSEcCtD
Dolutegravir—Flatulence—Sunitinib—pancreatic cancer	0.000914	0.00419	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.000906	0.00416	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Gemcitabine—pancreatic cancer	0.000901	0.00413	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Epirubicin—pancreatic cancer	0.000862	0.00395	CcSEcCtD
Dolutegravir—Nervous system disorder—Erlotinib—pancreatic cancer	0.000858	0.00393	CcSEcCtD
Dolutegravir—Skin disorder—Erlotinib—pancreatic cancer	0.00085	0.0039	CcSEcCtD
Dolutegravir—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.000845	0.00387	CcSEcCtD
Dolutegravir—Inflammation—Epirubicin—pancreatic cancer	0.00084	0.00385	CcSEcCtD
Dolutegravir—Urethral disorder—Gemcitabine—pancreatic cancer	0.000838	0.00385	CcSEcCtD
Dolutegravir—Abnormal dreams—Epirubicin—pancreatic cancer	0.000806	0.00369	CcSEcCtD
Dolutegravir—Abdominal pain upper—Docetaxel—pancreatic cancer	0.000801	0.00368	CcSEcCtD
Dolutegravir—Insomnia—Tamoxifen—pancreatic cancer	0.0008	0.00367	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—pancreatic cancer	0.000797	0.00366	CcSEcCtD
Dolutegravir—Immune system disorder—Irinotecan—pancreatic cancer	0.000793	0.00364	CcSEcCtD
Dolutegravir—Insomnia—Erlotinib—pancreatic cancer	0.000791	0.00363	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.000784	0.0036	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—pancreatic cancer	0.000778	0.00357	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.000774	0.00355	CcSEcCtD
Dolutegravir—Immune system disorder—Gemcitabine—pancreatic cancer	0.000772	0.00354	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000763	0.0035	CcSEcCtD
Dolutegravir—Fatigue—Tamoxifen—pancreatic cancer	0.000762	0.0035	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000755	0.00346	CcSEcCtD
Dolutegravir—Fatigue—Erlotinib—pancreatic cancer	0.000754	0.00346	CcSEcCtD
Dolutegravir—Flatulence—Irinotecan—pancreatic cancer	0.000753	0.00345	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—pancreatic cancer	0.000745	0.00342	CcSEcCtD
Dolutegravir—Nervous system disorder—Sunitinib—pancreatic cancer	0.000743	0.00341	CcSEcCtD
Dolutegravir—Rash maculo-papular—Epirubicin—pancreatic cancer	0.000741	0.0034	CcSEcCtD
Dolutegravir—Skin disorder—Sunitinib—pancreatic cancer	0.000735	0.00337	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.000723	0.00332	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.000715	0.00328	CcSEcCtD
Dolutegravir—Neutropenia—Docetaxel—pancreatic cancer	0.000709	0.00325	CcSEcCtD
Dolutegravir—Abdominal pain—Tamoxifen—pancreatic cancer	0.000699	0.00321	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NFE2L2—pancreatic cancer	0.000699	0.00622	CbGpPWpGaD
Dolutegravir—Abdominal pain—Erlotinib—pancreatic cancer	0.000691	0.00317	CcSEcCtD
Dolutegravir—Vertigo—Irinotecan—pancreatic cancer	0.000687	0.00315	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.000686	0.00314	CcSEcCtD
Dolutegravir—Insomnia—Sunitinib—pancreatic cancer	0.000685	0.00314	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFA—pancreatic cancer	0.000667	0.00594	CbGpPWpGaD
Dolutegravir—Renal failure—Docetaxel—pancreatic cancer	0.000665	0.00305	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000654	0.003	CcSEcCtD
Dolutegravir—Fatigue—Sunitinib—pancreatic cancer	0.000653	0.00299	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A2—pancreatic cancer	0.000652	0.00581	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000651	0.00299	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.000639	0.00293	CcSEcCtD
Dolutegravir—Asthenia—Tamoxifen—pancreatic cancer	0.000634	0.00291	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000629	0.00289	CcSEcCtD
Dolutegravir—Asthenia—Erlotinib—pancreatic cancer	0.000628	0.00288	CcSEcCtD
Dolutegravir—Pruritus—Tamoxifen—pancreatic cancer	0.000625	0.00287	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—pancreatic cancer	0.000622	0.00285	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000619	0.00284	CcSEcCtD
Dolutegravir—Pruritus—Erlotinib—pancreatic cancer	0.000619	0.00284	CcSEcCtD
Dolutegravir—Nervous system disorder—Irinotecan—pancreatic cancer	0.000612	0.00281	CcSEcCtD
Dolutegravir—Hepatitis—Docetaxel—pancreatic cancer	0.000607	0.00278	CcSEcCtD
Dolutegravir—Diarrhoea—Tamoxifen—pancreatic cancer	0.000605	0.00277	CcSEcCtD
Dolutegravir—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000599	0.00275	CcSEcCtD
Dolutegravir—Abdominal pain—Sunitinib—pancreatic cancer	0.000599	0.00275	CcSEcCtD
Dolutegravir—Diarrhoea—Erlotinib—pancreatic cancer	0.000598	0.00275	CcSEcCtD
Dolutegravir—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000596	0.00273	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—pancreatic cancer	0.000595	0.00273	CcSEcCtD
Dolutegravir—Skin disorder—Gemcitabine—pancreatic cancer	0.00059	0.00271	CcSEcCtD
Dolutegravir—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000586	0.00269	CcSEcCtD
Dolutegravir—Dizziness—Tamoxifen—pancreatic cancer	0.000585	0.00268	CcSEcCtD
Dolutegravir—Dizziness—Erlotinib—pancreatic cancer	0.000578	0.00265	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—pancreatic cancer	0.000575	0.00264	CcSEcCtD
Dolutegravir—Insomnia—Irinotecan—pancreatic cancer	0.000564	0.00259	CcSEcCtD
Dolutegravir—Vomiting—Tamoxifen—pancreatic cancer	0.000562	0.00258	CcSEcCtD
Dolutegravir—Hypersensitivity—Sunitinib—pancreatic cancer	0.000558	0.00256	CcSEcCtD
Dolutegravir—Rash—Tamoxifen—pancreatic cancer	0.000557	0.00256	CcSEcCtD
Dolutegravir—Dermatitis—Tamoxifen—pancreatic cancer	0.000557	0.00255	CcSEcCtD
Dolutegravir—Vomiting—Erlotinib—pancreatic cancer	0.000556	0.00255	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000554	0.00254	CcSEcCtD
Dolutegravir—Headache—Tamoxifen—pancreatic cancer	0.000554	0.00254	CcSEcCtD
Dolutegravir—Rash—Erlotinib—pancreatic cancer	0.000552	0.00253	CcSEcCtD
Dolutegravir—Dermatitis—Erlotinib—pancreatic cancer	0.000551	0.00253	CcSEcCtD
Dolutegravir—Insomnia—Gemcitabine—pancreatic cancer	0.00055	0.00252	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—pancreatic cancer	0.000548	0.00251	CcSEcCtD
Dolutegravir—Headache—Erlotinib—pancreatic cancer	0.000548	0.00251	CcSEcCtD
Dolutegravir—Asthenia—Sunitinib—pancreatic cancer	0.000543	0.00249	CcSEcCtD
Dolutegravir—Abdominal pain upper—Epirubicin—pancreatic cancer	0.00054	0.00248	CcSEcCtD
Dolutegravir—Insomnia—Fluorouracil—pancreatic cancer	0.00054	0.00248	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000538	0.00247	CcSEcCtD
Dolutegravir—Fatigue—Irinotecan—pancreatic cancer	0.000538	0.00247	CcSEcCtD
Dolutegravir—Pruritus—Sunitinib—pancreatic cancer	0.000536	0.00246	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—pancreatic cancer	0.000532	0.00244	CcSEcCtD
Dolutegravir—Nausea—Tamoxifen—pancreatic cancer	0.000525	0.00241	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000525	0.00241	CcSEcCtD
Dolutegravir—Fatigue—Gemcitabine—pancreatic cancer	0.000524	0.0024	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000522	0.00239	CcSEcCtD
Dolutegravir—Nausea—Erlotinib—pancreatic cancer	0.00052	0.00238	CcSEcCtD
Dolutegravir—Diarrhoea—Sunitinib—pancreatic cancer	0.000518	0.00238	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000516	0.00237	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000513	0.00235	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00051	0.00234	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HSPA1A—pancreatic cancer	0.000502	0.00447	CbGpPWpGaD
Dolutegravir—Dizziness—Sunitinib—pancreatic cancer	0.000501	0.0023	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.0005	0.00229	CcSEcCtD
Dolutegravir—Abdominal pain—Irinotecan—pancreatic cancer	0.000493	0.00226	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000483	0.00221	CcSEcCtD
Dolutegravir—Vomiting—Sunitinib—pancreatic cancer	0.000481	0.00221	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—pancreatic cancer	0.000478	0.00219	CcSEcCtD
Dolutegravir—Rash—Sunitinib—pancreatic cancer	0.000477	0.00219	CcSEcCtD
Dolutegravir—Dermatitis—Sunitinib—pancreatic cancer	0.000477	0.00219	CcSEcCtD
Dolutegravir—Headache—Sunitinib—pancreatic cancer	0.000474	0.00218	CcSEcCtD
Dolutegravir—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000461	0.00212	CcSEcCtD
Dolutegravir—Hypersensitivity—Irinotecan—pancreatic cancer	0.00046	0.00211	CcSEcCtD
Dolutegravir—Nausea—Sunitinib—pancreatic cancer	0.00045	0.00206	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—pancreatic cancer	0.000448	0.00206	CcSEcCtD
Dolutegravir—Asthenia—Irinotecan—pancreatic cancer	0.000448	0.00205	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000447	0.00205	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000445	0.00396	CbGpPWpGaD
Dolutegravir—Neutropenia—Doxorubicin—pancreatic cancer	0.000442	0.00203	CcSEcCtD
Dolutegravir—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00044	0.00202	CcSEcCtD
Dolutegravir—Asthenia—Gemcitabine—pancreatic cancer	0.000436	0.002	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000431	0.00198	CcSEcCtD
Dolutegravir—Pruritus—Gemcitabine—pancreatic cancer	0.00043	0.00197	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000427	0.00196	CcSEcCtD
Dolutegravir—Diarrhoea—Irinotecan—pancreatic cancer	0.000427	0.00196	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—pancreatic cancer	0.000423	0.00194	CcSEcCtD
Dolutegravir—Pruritus—Fluorouracil—pancreatic cancer	0.000423	0.00194	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—pancreatic cancer	0.000419	0.00192	CcSEcCtD
Dolutegravir—Diarrhoea—Gemcitabine—pancreatic cancer	0.000416	0.00191	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—pancreatic cancer	0.000415	0.0019	CcSEcCtD
Dolutegravir—Dizziness—Irinotecan—pancreatic cancer	0.000412	0.00189	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—pancreatic cancer	0.000409	0.00188	CcSEcCtD
Dolutegravir—Diarrhoea—Fluorouracil—pancreatic cancer	0.000409	0.00187	CcSEcCtD
Dolutegravir—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000404	0.00185	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—pancreatic cancer	0.000401	0.00184	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000399	0.00183	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	0.000398	0.00354	CbGpPWpGaD
Dolutegravir—Vomiting—Irinotecan—pancreatic cancer	0.000397	0.00182	CcSEcCtD
Dolutegravir—Dizziness—Fluorouracil—pancreatic cancer	0.000395	0.00181	CcSEcCtD
Dolutegravir—Rash—Irinotecan—pancreatic cancer	0.000393	0.0018	CcSEcCtD
Dolutegravir—Dermatitis—Irinotecan—pancreatic cancer	0.000393	0.0018	CcSEcCtD
Dolutegravir—Headache—Irinotecan—pancreatic cancer	0.000391	0.00179	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—pancreatic cancer	0.00039	0.00179	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	0.00039	0.00347	CbGpPWpGaD
Dolutegravir—Vomiting—Gemcitabine—pancreatic cancer	0.000386	0.00177	CcSEcCtD
Dolutegravir—Rash—Gemcitabine—pancreatic cancer	0.000383	0.00176	CcSEcCtD
Dolutegravir—Dermatitis—Gemcitabine—pancreatic cancer	0.000383	0.00176	CcSEcCtD
Dolutegravir—Headache—Gemcitabine—pancreatic cancer	0.000381	0.00175	CcSEcCtD
Dolutegravir—Vomiting—Fluorouracil—pancreatic cancer	0.00038	0.00174	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—pancreatic cancer	0.000379	0.00174	CcSEcCtD
Dolutegravir—Rash—Fluorouracil—pancreatic cancer	0.000377	0.00173	CcSEcCtD
Dolutegravir—Dermatitis—Fluorouracil—pancreatic cancer	0.000376	0.00173	CcSEcCtD
Dolutegravir—Headache—Fluorouracil—pancreatic cancer	0.000374	0.00172	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000374	0.00172	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000372	0.00171	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—pancreatic cancer	0.000372	0.00171	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	0.000371	0.00331	CbGpPWpGaD
Dolutegravir—Urethral disorder—Doxorubicin—pancreatic cancer	0.000371	0.0017	CcSEcCtD
Dolutegravir—Nausea—Irinotecan—pancreatic cancer	0.00037	0.0017	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—pancreatic cancer	0.00037	0.0017	CcSEcCtD
Dolutegravir—Nausea—Gemcitabine—pancreatic cancer	0.000361	0.00166	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—pancreatic cancer	0.000359	0.00164	CcSEcCtD
Dolutegravir—Nausea—Fluorouracil—pancreatic cancer	0.000355	0.00163	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000353	0.00162	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—pancreatic cancer	0.000351	0.00161	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—pancreatic cancer	0.000342	0.00157	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—pancreatic cancer	0.000341	0.00156	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—pancreatic cancer	0.000332	0.00152	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—pancreatic cancer	0.000325	0.00149	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—pancreatic cancer	0.00032	0.00147	CcSEcCtD
Dolutegravir—Hypersensitivity—Docetaxel—pancreatic cancer	0.000318	0.00146	CcSEcCtD
Dolutegravir—Asthenia—Docetaxel—pancreatic cancer	0.000309	0.00142	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—pancreatic cancer	0.000305	0.0014	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000301	0.00138	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—pancreatic cancer	0.000296	0.00136	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—pancreatic cancer	0.000295	0.00135	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—pancreatic cancer	0.000285	0.00131	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—pancreatic cancer	0.000285	0.00131	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—pancreatic cancer	0.000282	0.0013	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000279	0.00128	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—pancreatic cancer	0.000274	0.00126	CcSEcCtD
Dolutegravir—Rash—Docetaxel—pancreatic cancer	0.000272	0.00125	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—pancreatic cancer	0.000272	0.00125	CcSEcCtD
Dolutegravir—Headache—Docetaxel—pancreatic cancer	0.00027	0.00124	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000264	0.00121	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—pancreatic cancer	0.000263	0.00121	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—pancreatic cancer	0.000261	0.0012	CcSEcCtD
Dolutegravir—Nausea—Docetaxel—pancreatic cancer	0.000256	0.00117	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000251	0.00115	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—pancreatic cancer	0.000251	0.00115	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—pancreatic cancer	0.000243	0.00112	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000238	0.00109	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000232	0.00107	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—pancreatic cancer	0.000232	0.00106	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—pancreatic cancer	0.00023	0.00105	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.00022	0.00101	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—pancreatic cancer	0.000214	0.000983	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—pancreatic cancer	0.000213	0.000976	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—pancreatic cancer	0.000209	0.000957	CcSEcCtD
Dolutegravir—Pruritus—Epirubicin—pancreatic cancer	0.000206	0.000944	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—pancreatic cancer	0.000199	0.000913	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000198	0.000909	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—pancreatic cancer	0.000193	0.000886	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—pancreatic cancer	0.000192	0.000882	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—pancreatic cancer	0.00019	0.000873	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—pancreatic cancer	0.000185	0.000848	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—pancreatic cancer	0.000184	0.000844	CcSEcCtD
Dolutegravir—Rash—Epirubicin—pancreatic cancer	0.000183	0.000841	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—pancreatic cancer	0.000183	0.00084	CcSEcCtD
Dolutegravir—Headache—Epirubicin—pancreatic cancer	0.000182	0.000836	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—pancreatic cancer	0.000178	0.000816	CcSEcCtD
Dolutegravir—Nausea—Epirubicin—pancreatic cancer	0.000173	0.000792	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PRSS1—pancreatic cancer	0.000172	0.00153	CbGpPWpGaD
Dolutegravir—Vomiting—Doxorubicin—pancreatic cancer	0.000171	0.000785	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—pancreatic cancer	0.00017	0.000778	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—pancreatic cancer	0.00017	0.000777	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—pancreatic cancer	0.000169	0.000773	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—pancreatic cancer	0.00016	0.000733	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB1—pancreatic cancer	0.000158	0.00141	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ARG2—pancreatic cancer	0.000149	0.00132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMP—pancreatic cancer	0.00013	0.00116	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GLP1R—pancreatic cancer	0.000105	0.000933	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DPYD—pancreatic cancer	0.000103	0.000918	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC2A2—pancreatic cancer	9.79e-05	0.000871	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CD44—pancreatic cancer	7.58e-05	0.000675	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GCG—pancreatic cancer	7.27e-05	0.000647	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STK11—pancreatic cancer	6.83e-05	0.000608	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—pancreatic cancer	5.88e-05	0.000523	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—APOE—pancreatic cancer	4.78e-05	0.000425	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—pancreatic cancer	4.31e-05	0.000384	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARG—pancreatic cancer	4.16e-05	0.000371	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	3.79e-05	0.000338	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	3.3e-05	0.000294	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—pancreatic cancer	3.27e-05	0.000292	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—pancreatic cancer	2.86e-05	0.000254	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	2.01e-05	0.000179	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—pancreatic cancer	1.65e-05	0.000147	CbGpPWpGaD
